基本信息 产品详情 公司简介 推荐产品
网站主页 化合物 IRDABISANT HYDROCHLORIDE 化合物 Irdabisant hydrochloride
  • 化合物 Irdabisant hydrochloride|T61197|TargetMol

化合物 Irdabisant hydrochloride|T61197|TargetMol

Irdabisant hydrochloride
10600 25mg 起订
17500 100mg 起订
13800 50mg 起订
上海 更新日期:2025-11-17

TargetMol中国(陶术生物)

VIP2年
联系人:邵小姐
手机:15002134094 拨打
邮箱:marketing@targetmol.cn

产品详情:

中文名称:
化合物 Irdabisant hydrochloride
英文名称:
Irdabisant hydrochloride
CAS号:
1005398-61-7
品牌:
TargetMol
产地:
美国
保存条件:
Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature.
产品类别:
抑制剂
货号:
T61197

Product Introduction

Bioactivity

名称Irdabisant hydrochloride
描述Irdabisant hydrochloride (CEP-26401) is a selective, orally active, and blood-brain barrier (BBB) penetrant histamine H3 receptor (H3R) inverse agonist/inverse agonist, demonstrating high affinity with K*i values of 7.2 nM and 2.0 nM for rat and human H3R respectively. It exhibits relatively low hERG current inhibitory activity, with an IC*50 of 13.8 μM. This compound has been shown to enhance cognition and promote wakefulness in rat social recognition models, suggesting potential applications in schizophrenia or cognitive impairment research.
体外活性Irdabisant (CEP-26401, compound 8a) shows antagonist activity with K b, app values of 1.0 nM and 0.4 nM for rat H3R and human H3R, respectively; shows inverse agonist activity with EC 50 values of 2.0 nM and 1.1 nM for rat H3R and human H3R, respectively [1]. Irdabisant has moderate activity at Muscarinic M 2 (K i = 3.7 ± 0.0 μM) and Adrenergic α 1A (K i = 9.8 ± 0.3 μM) receptors, Dopamine transporters (K i = 11 ± 2 μM), Norepinephrine transporters (K i = 10 ± 1 μM), and phosphodiesterase PDE3 (IC 50 = 15 ± 1 μM) [1]. Irdabisant inhibits the cytochrome P450 enzymes CYP1A2, 2C9, 2C19, 2D6, and 3A4 with IC 50 values of greater than 30 μM, indicating less potential for drug-drug interactions [1].
体内活性CEP-26401 (0.01-0.3 mg/kg; p.o.; single dosage) dose-dependently inhibits H3R agonist RAMH -induced dipsogenia [1]. CEP-26401 (0.0001-0.1 mg/kg; i.v. or p.o.; single dosage) improves performance in the rat social recognition model of short-term memory [1]. CEP-26401 (3-30 mg/kg; p.o.; single dosage) exhibits wake-promoting activity in rat [2]. CEP-26401 (3-30 mg/kg; i.p.) increases prepulse inhibition (PPI) in DBA/2NCrl mice [2]. CEP-26401 (1 mg/kg for i.v. and 3 mg/kg for p.o.; single dosage) is rapidly absorbed with high oral bioavailability in rat and monkey, and shows a moderate clearance in monkey and dog compared to the rat [1]. Pharmacokinetic Parameters of Irdabisant (compound 8a) in rats, dogs and monkeys [1]. Rat Dog Monkey i.v. t 1/2 (h) 2.6 2.9 5.4 i.v. V d (L/kg) 9.4 3.5 ± 1.1 3.8 ± 0.9 i.v. CL (mL/min/kg) 42 13.2 ± 1.5 7.7 ± 1.8 p.o. t 1/2 (L/kg) 2.9 2.7 5.0 p.o. AUC (ng·h/mL) 984 1190 ± 180 1919 ± 611 p.o. C max (ng/mL) 270 230 ± 70 760 ± 74 p.o. F (%) 83 22 ± 2 83 ± 18 Brain to plasma ratio 2.6 ± 0.2 2.4 ± 0.4 / Animal Model: Male Sprague-Dawley rats (i.p. 10 mg/kg RAMH-induced dipsogenia model) [1] Dosage: 0.01-0.3 mg/kg Administration: p.o.; single dosage Result: Dose-dependently inhibited H3R agonist RAMH -induced dipsogenia (which manifests as water drinking) with an EC 50 value of 0.06 mg/kg. Animal Model: Male Sprague-Dawley rats (adult rats were briefly exposed to a juvenile rat for build social recognition model) [2] Dosage: 0.0001, 0.001, 0.01 and 0.1 mg/kg for i.p.; 0.01 and 0.1 mg/kg for p.o. Administration: i.v. or p.o.; single dosage Result: Effectively reduced the ratio of investigation duration (RID) at doses over the range from 0.001 to 0.1 mg/kg i.p. and at 0.01 and 0.1 mg/kg p.o., demonstrating potent enhancement of short-term sensory memory in this model. Animal Model: Male Sprague-Dawley rats [2] Dosage: 3, 10 and 30 mg/kg Administration: p.o.; single dosage Result: Exhibited robust wake promotion with the treated animals awake 90% of the time up to 3 h postdosing at 30 mg/kg. Animal Model: Male Sprague-Dawley rats, male beagle dogs and male cynomolgus monkeys [1] Dosage: 1 mg/kg for i.v. and 3 mg/kg for p.o. Administration: i.v. and p.o. Result: Exhibited rapid absorption with high oral bioavailability in rat and monkey, and showed a moderate clearance in monkey and dog compared to the rat. Animal Model: Male DBA/2NCrl mice (19-27 g; 7-9 weeks) [2] Dosage: 3, 10 and 30 mg/kg Administration: i.p.; single dosage Result: Increased prepulse inhibition (PPI) in DBA/2NCrl mice, whereas the antipsychotic Risperidone is effective at 0.3 and 1 mg/kg i.p..
存储条件Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature.
相关产品Famotidine | Meclizine dihydrochloride | Lidocaine | Betahistine mesylate | Mebhydrolin napadisylate | Alginic acid | Sodium butanoate | Mirtazapine | Trazodone hydrochloride | Mianserin hydrochloride | Chlorphenesin | Loratadine
Irdabisant hydrochloride|TargetMol

公司简介

TargetMol Chemicals Inc. 总部位于马萨诸塞州波士顿,致力于为全球生化领域科学家的研究提供专业的产品和服务。TargetMol?品牌的客户群分布于40多个国家和地区,已发展成为全球知名的化合物库和小分子化合物研究供应商。 TargetMol?可提供160多种满足不同需求的化合物库,以及多种类型的生化试剂产品,包括12000多种抑制剂、16000多种天然产物和各类多肽、抗体、生命科学试剂盒等,此外,我们还建设有CADD(计算机辅助药物设计)研究中心、药理实验室、药化合成平台三大技术中心,全方位满足客户的定制需求。 凭借我们优质的产品和服务、快速高效的全球供应链和专业的技术支持,我们将有效帮助您缩短研发周期,取得更成功的结果。

成立日期 (13年)
注册资本 589.8595万人民币
员工人数 100-500人
年营业额 ¥ 1亿以上
经营模式 贸易,工厂,试剂,定制,服务
主营行业 中间体,天然产物,生物化工,化学试剂,生物技术服务

化合物 Irdabisant hydrochloride相关厂家报价

内容声明
拨打电话 立即询价